| 1 |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemo-therapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344 (11): 783-792.
|
| 2 |
Hudis CA. Trastuzumab-mechanism of action and use in clinical practice[J]. N Engl J Med, 2007, 357 (1): 39-51.
|
| 3 |
Santos MH. Detection of subclinical Trastuzumab-induced cardiotoxicity in patients with breast cancer[J]. Arq Bras Cardiol, 2013, 101 (1): 2-3.
|
| 4 |
Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. J Clin Oncol, 2002, 20 (5): 1215-1221.
|
| 5 |
Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta analysis[J]. Cancer Treat Rev, 2011, 37 (4): 312-320.
|
| 6 |
Tarantini L, Gori S, Faggiano P, et al. Adjuvant trastuzu-mab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis[J]. Ann Oncol, 2012, 23 (12): 3058-3063.
|
| 7 |
尹丽慧，沃兴德. 参麦注射液的药理和临床研究进展[J]. 浙江中医学院学报，2001，25(6):65-68.
|
| 8 |
薛卫成. 介绍乳腺癌TNM分期系统（第7版）[J]. 诊断病理学杂志，2010，17(4):241-244.
|
| 9 |
Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2012, 30 (31): 3792–3799.
|
| 10 |
潘宏铭，耿宝琴. 肿瘤化疗的毒副反应和防治[M]. 3版. 上海：上海科学技术出版社，2001，46-52.
|
| 11 |
Colombo A, Meroni CA, Cipolla CM, et al. Managing cardiotoxicity of chemotherapy[J]. Curr Treat Options Cardiovasc Med, 2013, 15 (4): 410-424.
|
| 12 |
周玥，傅永平. 血浆B型利钠肽在不同左心功能肺心病患者中的临床价值探讨[J/CD]. 中华危重症医学杂志（电子版），2016，9(3):184-186.
|
| 13 |
Seicean S, Seicean A, Alan N, et al. Cardioprotective effect of Beta-Adrenoceptor blockade in breast cancer patients undergoing chemotherapy: a follow-up study of heart failure[J]. Circ Heart Fail, 2013, 6 (3): 420-426.
|
| 14 |
Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition[J]. Circulation, 2006, 114 (23): 2474-2481.
|
| 15 |
金先桥，段生福，牛汝辑，等. 参麦注射液及其配伍对慢性缺氧鼠血气及血液动力学的影响[J]. 中国中西医结合杂志，1995，15(3):162-164.
|
| 16 |
王艳蕾，景友玲，赵景霞，等. 参麦注射液对肢体缺血再灌注时肺脂质过氧化损伤的防护作用[J].中国应用生理学杂志，2006，22(1):13-15.
|
| 17 |
黄翠萍，杨和平，张珍祥. 参麦注射液对脂多糖诱导大鼠急性肺损伤防护机制探讨[J]. 中华结核和呼吸杂志，2005，28(1):67-68.
|
| 18 |
梁晋川，黄宁. 参麦注射液在心血管疾病中的临床应用进展[J]. 中国实用医药，2006，1(4):48-49.
|
| 19 |
邹涛. 参麦注射液不良反应65例分析[J]. 基层医学论坛，2012，16(1):35-36.
|